Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

ward to further evaluating the correlation between rash and clinical activity, as well as alternate dosing schedules of CR011-vcMMAE," commented Dr. Hwu.

CuraGen is currently enrolling patients into a Phase I portion of this trial to evaluate more frequent dosing schedules of CR011-vcMMAE, including a weekly and a two out of every three-week regimen, to explore if more frequent administration can provide additional activity in patients with metastatic melanoma. CR011-vcMMAE is also being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. CuraGen anticipates providing updated data from the ongoing melanoma and breast cancer studies in the first half of 2009.

"While we continue to finalize data from this study, develop data from more frequent dosing in patients with metastatic melanoma and from the Phase II study in patients with breast cancer, we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development," added Dr. Shannon. "The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential."

In addition to M. D. Anderson, other sites participating in the melanoma trial include Yale Cancer Center, New Haven, CT; The Angeles Clinic and Research Institute, Santa Monica, CA; and New York University Medical Center, New York, NY.

Reprints of the presentation will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@curagen.com.

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 ... has announced the addition of the  "China ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in China impacted ... in consumption concept, dietary habit, way of ...
(Date:10/17/2014)... 17, 2014 Investor-Edge has initiated ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), ... on these five companies can be accessed at: ... October 16, 2014, ended on a mixed note as ...
(Date:10/17/2014)... BALTIMORE , Oct. 17, 2014  Ameritox SM ... announced the appointment of Thomas Smith , M.D., ... lead a field-based team offering scientific resources for healthcare ... Smith has held leadership positions at a variety of ... will benefit both the pain and behavioral health sides ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... Pharmaceuticals, Inc. announced the appointment of Dave Lemus as ... 2011.  Lemus will join the leadership team at Sigma-Tau ... For the past 13 years, Lemus served as chief ... Segment; TecDAX), one of the Europe,s leading biotechnology companies ...
... Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... indicates that an Abbreviated New Drug Application (ANDA) for ... sulfate) capsules was submitted on March 7, 2011. The ... 2011. Avanir intends to vigorously enforce its ...
Cached Medicine Technology:Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance 2Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 2Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 3Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA 4
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
(Date:10/20/2014)... 2014 JZ Fitness, an independently operated ... wellness programming, authorship, international lecturing and community wellness, created ... the release of the JZ Fitness nutrition app, available ... coaching thousands of individuals on nutrition, Jenn Zerling (“JZ”) ... not require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 ... Matthew Voicheck as Assistant Director of their ... role in managing the innovative turnkey drug sourcing, ... , Matthew brings over 12 years of industry ... joins Myoderm at the peak of their international ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... rate since 1999, WASHINGTON, Sept. 11 ... eight years, marking the fourth,consecutive year premium increases ... Published by the Kaiser Family Foundation and ... 2007 Annual Survey found,that health insurance premiums increased ...
... Sept. 11 GlaxoSmithKline (NYSE:,GSK) believes that conclusions ... Nissen et. al. and Furberg et. al. in ... not confirm a difference in the,safety profile of ... that are common to all meta-analyses, by,the authors, ...
... Local Business Community Comes Together in Support of Event, ... still available for the fourth annual Detroit Uncorked, one ... Center, is held at Ford Field, Sept. 28 from ... Motor Company and Ford Field and created and,organized by ...
... Pennsylvania with substantial experience in infection control ... The Pennsylvania,Patient Safety Authority,s Board of Directors ... to help implement Act 52 of 2007. The,act ... in July to help reduce and,eliminate healthcare-associated infections ...
... Journal of the America Heart Association confirms that when young ... influence their heart disease risk later in life. ... have landmark implications on how children should be taught to ... reduction in intake of saturated fat, was found to be ...
... 11 (HealthDay News) -- Carvedilol, a newer member of the beta ... failure, did not help children with the condition, a new study ... it -- was almost exactly the same for 103 young heart-failure ... got a placebo. , "Heart failure in children is both not ...
Cached Medicine News:Health News:Health Insurance Premium Growth Slows for Fourth Straight Year 2Health News:GlaxoSmithKline Responds to JAMA Articles 2Health News:GlaxoSmithKline Responds to JAMA Articles 3Health News:GlaxoSmithKline Responds to JAMA Articles 4Health News:GlaxoSmithKline Responds to JAMA Articles 5Health News:Tickets Still Available for Detroit Uncorked; 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 3Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 4Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 5Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 6Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 7Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 8Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 9Health News:Children who learn heart healthy eating habits lower heart disease risk 2Health News:Children who learn heart healthy eating habits lower heart disease risk 3Health News:Beta Blocker Doesn't Help Children With Heart Failure 2
The PICO50 is used for arterial line sampling....
The safePICO is a prebarcoded arterial sampler that helps you ensure patient and caregiver safety. SafePICO is part of 1st automatic, the worlds first automatic blood gas analysis system....
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
Medicine Products: